

LPIXEL announces initiation of AI System development for cell evaluation with Astellas Pharma

05 June 2019 | News

During the project, Astellas will access LPIXEL's AI-instilled image analysis solution, IMACEL Lab



LPIXEL Inc., a leader in image analysis and processing technology in life science and medical research has announced the initiation of the artificial intelligence (AI) system development for cell evaluation with Astellas Pharma Inc.

During the project, Astellas will access LPIXEL's AI-instilled image analysis solution, IMACEL Lab, for the cell selection and management processes in conducting research on regenerative medicine and cell therapy.

AI for Cell Culture Quality Control on Regenerative Medicine and Cell Therapy

In recent years, much attention has been given to regenerative medicine and cell therapy, which is the field of science aimed at repairing damaged cells and tissues. The Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas, is carrying out biopharmaceutical research and development including work on regenerative medicine and cell therapy.

In regenerative medicine and cell therapy, it is essential to maintain and select cells suitable for treatment. IMACEL Lab will assist in cell selection and maintenance.

IMACEL Lab aims to solve various needs in life science research and development, particularly in the medical, pharmaceutical and agricultural sectors by combining AI with the image analysis technologies that the members of the company have been developing ever since its inception at the University of Tokyo laboratory in the year 2000. As with Astellas, LPIXEL will foster the development of new values through each of its partnerships.